Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients - A prospective case-controlled study

American Journal of Transplantation

Volumn 9, Issue 7, 2009, Pages 1650-1656

  Kofler, S ^a   Shvets, N ^a   Bigdeli, A K ^a   Konig M A ^a   Kaczmarek, P ^a   Deutsch, M A ^a   Vogeser, M ^b   Steinbeck, G ^a   Reichart, B ^a   Kaczmarek, I ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Heart transplantation; Mycophenolic acid; Pantoprazole; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

BILIRUBIN; C REACTIVE PROTEIN; CHOLINESTERASE; CREATININE; DILTIAZEM; FUROSEMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANTOPRAZOLE; PREDNISOLONE; PROTON PUMP INHIBITOR; SIMVASTATIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AREA UNDER THE CURVE; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; STANDARDIZATION; STATISTICAL SIGNIFICANCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ACUTE DISEASE; ADULT; CASE-CONTROL STUDIES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; RISK FACTORS; TACROLIMUS;

EID: 67649655600     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02682.x     Document Type: Article

References (30)

1. Kobashigawa JA, Meiser BM. Review of major clinical trials with mycophenolate mofetil in cardiac transplantation. Transplantation 2005 80 (Suppl S235 S243.
2. Keogh A. Long-term benefits of mycophenolate mofetil after heart transplantation. Transplantation 2005 79 (Suppl S45 S46.
3. Taylor DO, Edwards LB, Boucek MM et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth official adult heart transplant report - 2007. J Heart Lung Transplant 2007 26 : 769 781. (Pubitemid 47199081)
4. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007 46 : 13 58. (Pubitemid 46091591)
5. Kaczmarek I, Bigdeli AK, Vogeser M et al. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients. Ther Drug Monit 2008 30 : 419 427.
6. Le Meur Y, Büchler M, Thierry A et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007 7 : 2496 2503. (Pubitemid 47566324)
7. Díaz B, González Vilchez F, Almenar L et al. Gastrointestinal complications in heart transplant patients: MITOS study. Transplant Proc 2007 39 : 2397 2400. (Pubitemid 47418211)
8. Miura M, Satoh S, Inoue K et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit 2008 30 : 46 51. (Pubitemid 351161098)
9. Shipkova M, Niedmann PD, Armstrong VW et al. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clin Chem 1998 44 : 1481 1488. (Pubitemid 28309109)
10. Miura M, Inoue K, Kagaya H et al. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. Biopharm Drug Dispos 2007 28 : 167 175. (Pubitemid 46824853)
11. Homma M, Itagaki F, Yuzawa K, Fukao K, Kohda Y. Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: Case of a renal transplant recipient with CYP2C19 gene mutation. Transplantation 2002 73 : 303 304. (Pubitemid 34112860)
12. Huber R, Hartmann M, Bliesath H, Lühmann R, Steinijans VW, Zech K. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996 34 : 185 194. (Pubitemid 26148501)
13. Pue MA, Laroche J, Meineke I, de Mey C. Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. Eur J Clin Pharmacol 1993 44 : 575 578. (Pubitemid 23197845)
14. Yacyshyn BR, Thomson AB. The clinical importance of proton pump inhibitor pharmacokinetics. Digestion 2002 66 : 67 78. (Pubitemid 35356686)
15. Bullingham R, Monroe S, Nicholls A, Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996 36 : 315 324. (Pubitemid 26125953)
16. Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): A short review. Transplant Proc 1996 28 : 925 929. (Pubitemid 26138486)
17. Zwerner J, Fiorentino D. Mycophenolate mofetil. Dermatol Ther 2007 20 : 229 238. (Pubitemid 350029312)
18. Tomiyama Y, Morii M, Takeguchi N. Specific proton pump inhibitors E3810 and lansoprazole affect the recovery process of gastric secretion in rats differently. Biochem Pharmacol 1994 48 : 2049 2055.
19. Van Hest RM, van Gelder T, Vulto AG, Mathot RA. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet 2005 44 : 1083 1096. (Pubitemid 41356393)
20. Pisupati J, Jain A, Burckart G et al. Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. J Clin Pharmacol 2005 45 : 34 41.
21. Weimert NA, Derotte M, Alloway RR, Woodle ES, Vinks AA. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: Potential clinical implications. Ther Drug Monit 2007 29 : 141 149. (Pubitemid 46716179)
22. Naesens M, Verbeke K, Vanrenterghem Y, Kuypers D. Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. Br J Clin Pharmacol 2007 63 : 541 547. (Pubitemid 46632575)
23. Tredger JM, Brown NW, Adams J et al. Monitoring mycophenolate in liver transplant recipients: Toward a therapeutic range. Liver Transpl 2004 10 : 492 502. (Pubitemid 38443588)
24. Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002 62 : 1060 1067. (Pubitemid 35316738)
25. Hunfeld NG, Mathot RA, Touw DJ et al. Effect of CYP2C19 * 2 and * 17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol 2008 65 : 752 760.
26. Galiwango PJ, Delgado DH, Yan R et al. Mycophenolate mofetil dose reduction for gastrointestinal intolerance is associated with increased rates of rejection in heart transplant patients. J Heart Lung Transplant 2008 27 : 72 77.
27. Kaczmarek I, Ertl B, Schmauss D et al. Preventing cardiac allograft vasculopathy: Long-term beneficial effects of mycophenolate mofetil. J Heart Lung Transplant 2006 25 : 550 556.
28. Meiser BM, Pfeiffer M, Schmidt D et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: Importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 1999 18 : 143 149. (Pubitemid 29159294)
29. Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003 3 : 534 542. (Pubitemid 36612836)
30. van Gelder T, Le Meur Y, Shaw LM et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006 28 : 145 154. (Pubitemid 44314941)